March 4, 2014
Takeda Pres. Yasuchika Hasegawa at Tokyo News Conference Takeda Pharmaceutical offered apologies on March 3 over its improper promotion of Blopress (candesartan), which used a large-scale clinical study that compared its best-selling angiotensin receptor blocker and the calcium channel blocker...read more